NCT04977076Recruiting
Comparison Between Direct Oral Anticoagulation (DOAC) Interruption and DOAC Continuation in Patients Undergoing Elective Invasive Coronary Angiography or Percutaneous Coronary Intervention
Source: ClinicalTrials.gov · Last updated 29 May 2026
Brief summary (registry, in English)
A prospective, multicenter, 1:1 randomized, investigator initiated study. Goal of this study is to examine the safety of uninterrupted periprocedural DOAC use.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 1270 (estimated)
- First submitted
- 20 Jul 2021
- Start date
- 1 Sept 2022
- Primary completion date
- 31 Dec 2027
- Lead sponsor
- Zuyderland Medisch Centrum
- NCT number
- NCT04977076
What you commit to
- Study type: Interventional
- Planned participants: 1270
- From 1 Sept 2022 to the primary completion date, 31 Dec 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patients initially presenting with Acute Coronary Syndrome (STEMI, NSTEMI, UA)
Lab values
- Calculated creatinine clearance \<30 mL/min
- History or condition associated with increased bleeding risk, as listed below:
- Major surgical procedure within 30 days before the procedure
- Known inaccessible radial artery during previous procedure
- History of GI bleeding in the previous 6 months
- History of intracranial, intraocular, spinal, or atraumatic intra-articular bleeding
- Chronic bleeding disorder
- Known intracranial neoplasm, arteriovenous malformation, or aneurysm
- Known anemia with last measured haemoglobin value \<6 mmol/L \[9.67 g/dL\]
- Current pregnancy or breast-feeding
- Known significant liver disease (e.g., acute clinical hepatitis, chronic active hepatitis, cirrhosis), or Alanine aminotransferase (ALT) \>3 x the upper limit of normal.
Age
- Patients \<18 years old
Other
- A potential subject who meets any of the following criteria will be excluded from participation in this study:
- Any of the following:
- Patients simultaneously participating in another clinical trial
- Participation in another clinical trial
Who the study is looking for
- Patients aged \>18 years using DOAC and undergoing elective ICA or PCI.
- Provided signed informed consent
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Zuyderland MC Coordinator of this site? Confirm its status | Heerlen | Netherlands | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.